

The Open Respiratory Medicine Journal

Content list available at: https://openrespiratorymedicinejournal.com

Supplementary Material

Real-life Effectiveness of Omalizumab in Patients with Severe Allergic Asthma: RELIEF Study

Mona Al Ahmad[1], Lilia Margarita Borboa Olivares[2], Alexandre Pinto Cardoso[3], Wagih Djazmati[4], Miguel Angel Vinuesa[5], María de Jesús García Domínguez[6], Alcindo Cerci Neto[7], Luis Ugalde Gamboa[8], Jason K. Lee[9], Nadine Pinho[10] and Paolo Tassinari[11,*]

[1]*Department of Microbiology, Faculty of Medicine, Kuwait University, Kuwait*
[2]*ISSSTEP, Puebla, México*
[3]*Instituto Doenças do Tórax UFRJ, Rio de Janeiro, Brazil*
[4]*Sheikh Khalifa Medical City, Abu Dhabi, UAE*
[5]*Sanatorio Británico, Rosario, Argentina*
[6]*Consultorio Médico de Guadalupe/CHPTR, ISSSTE Campeche, México*
[7]*Hospital Universitário da Universidade Estadual de Londrina, Londrina, Brazil*
[8]*Clínica Americana, San José, Costa Rica*
[9]*Evidence Based Medical Educator, Toronto, Ontario, Canada*
[10]*Global Drug Development, Novartis Biociencias S.A., Sao Paulo, Brazil*
[11]*Novartis Pharma AG, Basel, Switzerland*

1. INCLUSION CRITERIA

• Males and females aged ≥ 6 years (pediatrics) or aged ≥ 12 years (adolescents and adults) with physician diagnosed severe allergic asthma (SAA).

• Patients who had received a minimum of two consecutive doses of omalizumab co-administered with standard treatment, ICS + LABA with or without SABA and/or OCS, as required.

• Patients had to qualify for treatment with omalizumab as per the country specific requirements for reimbursement, the local guidelines and product monograph.

• Patients or, when applicable and allowable by law, their legal representatives, provided informed consent in accordance with the local legal and regulatory requirements.

2. EXCLUSION CRITERIA

• Patients who were enrolled and treated in a clinical trial, with either omalizumab or other asthma medication, at the time of the study

• Patients for whom treatment with omalizumab was contraindicated due to allergies or hypersensitivity to omalizumab or the excipients

• Patients on off-label use of omalizumab

• Patients with any condition that could have interfered with the assessment of the effect of omalizumab on SAA, such as chronic obstructive pulmonary disease (COPD) and other chronic lung diseases

• Patients with any condition that could seriously limit their ability to participate in the study including, but not limited to, cancer and mental disability.

Table S1. Analysis of pulmonary function (mITT).

-	Pediatrics	Adolescents and Adults	Overall
FEV_1			
Baseline	1.8 ± 0.34	2.0 ± 0.89	2.01 ± 0.87
Month 4	1.5 ± NE	2.3 ± 0.85	2.3 ± 0.85
Month 8	2.0 ± 0.34	2.0 ± 0.80	2.0 ± 0.79
Month 12	2.1 ± 0.32	2.0 ± 0.82	2.0 ± 0.80

(Table S1) contd.....

Month 18	2.1 ± 0.38	2.0 ± 0.84	2.0 ± 0.82
Month 24	2.2 ± 0.37	2.1 ± 0.91	2.1 ± 0.89
FVC			
Baseline	2.2 ± 0.56	2.8 ± 0.95	2.8 ± 0.95
Month 4	1.7 ± NE	3.2 ± 0.86	3.1 ± 0.92
Month 8	2.2 ± 0.53	2.7 ± 0.93	2.7 ± 0.93
Month 12	2.3 ± 0.53	2.7 ± 0.93	2.7 ± 0.92
Month 18	2.4 ± 0.50	2.7 ± 0.91	2.7 ± 0.90
Month 24	2.5 ± 0.61	2.7 ± 0.10	2.7 ± 0.98
PEF			
Baseline	245.7 ± 42.71	304.9 ± 116.59	302.7 ± 115.18
Month 4	259.3 ± NE	306.5 ± 124.21	303.8 ± 120.81
Month 8	278.6 ± 31.63	305.5 ± 118.27	304.6 ± 116.34
Month 12	287.6 ± 70.85	302.8 ± 124.26	302.2 ± 122.35
Month 18	280.2 ± 48.054	327.2 ±159.30	325.2 ± 156.51
Month 24	285.9 ± 55.38	382.8 ± 755.04	379.2 ± 741.13

mITT, Modified intent-to-treat
NE = Not Estimated

Table S2. List of principal investigators.

Principal Investigator	Country
Gherson Cukier	Panama
Mona Al Ahmad	Kuwait
Wagih Djazmati	United Arab Emirates
Bassam Mahboub	United Arab Emirates
Marco Antonio Camere Torrealva	Peru
Ricardo Sanchez	Peru
Hassan Mobayedh	Qatar
Carolina Venialgo	Argentina
Soledad Crisci	Argentina
Fabricio Pablo Sparvoli	Argentina
Verónica Giubergia	Argentina
Miguel Angel Vinuesa	Argentina
Susana Barayazarra	Argentina
Viviana Moyano	Argentina
Martin Maillo	Argentina
Miguel Bergna	Argentina
Ramon Alchapar	Argentina
Jussara Fiterman	Brazil
Alcindo Cerci Neto	Brazil
Alexandre Pinto Cardoso	Brazil
Delbert Dorscheid	Canada
Jacques Hebert	Canada
Pierre Alain Houle*	Canada
Jason Kihyuk Lee	Canada
Lyle Melenka	Canada
Bruno Paradis	Canada
Benavuth Pek	Canada
William Yang	Canada
Shahin Zanganeh	Canada
Patrick Killorn	Canada
Edison Morales	Colombia
Jorge Sanchez	Colombia
Jose William Pulido	Colombia

(Table S2) contd.....

Emilio Guevara	Costa Rica
Luis Ugalde	Costa Rica
Arturo Solís	Costa Rica
Lilia Maragrita Borboa Olivares	Mexico
María de Jesús García Domínguez	Mexico
Marco Antonio Fernandez Corzo	Mexico